Sclerostin, expressed in osteocytes and some chondrocytes, inhibits bone formation by acting on osteoblasts. Humanized monoclonal antibody treatments that target sclerostin may be benificial for the treatment of osteoporosis. Sclerostin expression is impaired in patients with ankylosing spondylitis. Immunohistochemistry and western blot analysis revealed considerable overexpression of sclerostin in the synovial tissues of patients with RA compared to those with OA. Serum sclerostin is increased in individuals with prostate cancer.
Swiss-Prot Accession Number: Q9BQB4